MARTI TECHNOLOGIES INC
MRTNYSE AMERICANTrading Snapshot
- Day Range
- $1.94 – $1.98
- 52-Week Range
- $1.12 – $2.75
- Volume
- $2.87B
- Avg Volume
- $3.01B
- Shares Outstanding
- 86.0M
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $39M
- Last Q Revenue
- $20M
- P/E Ratio
- -4.3
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-0.49
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +40.7%
Why Investors Own MRT
- ✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 33% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MARTI TECHNOLOGIES INC
MRT
StockOtter · stockotter.spaceAbout MARTI TECHNOLOGIES INC
Marti Technologies Inc. (MRT), headquartered in Istanbul, Turkey, specializes in urban mobility. The company provides city-dwellers across Turkey with a range of transportation solutions via its proprietary mobile application. This platform offers access to a diverse fleet of shared electric vehicles, including e-mopeds, e-bikes, and e-scooters. Marti Technologies was established in 2018.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Marti Increases Share Repurchase Authorization to $5 Million and Extends Program Through April 2027
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced that its Board of Directors (the “Board”) has increased the authori
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone pa
Marti's Ride-Hailing Service Reaches 4.90 Million Riders and 584 Thousand Registered Drivers, Exceeding September 30, 2026 Targets a Month Earlier Than Planned
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of September 2, 2026, Marti's ride-hailing service has re
Marti Technologies: Buy The Inflection Point
Marti Technologies (MRT) delivered a major operating inflection, turning adjusted EBITDA positive and expanding gross margin to 77%, while accelerating revenue growth. I maintain a speculative buy rating with a $3.88 pri
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript